Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed
Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS,
2 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
of myeloproliferative neoplasms is based on hematologic,
histopathologic, and molecular characteristics, including the BCR-ABL1
and JAK2 V617F or MPL and CALR. Although the different gene mutations
ought to be mutually exclusive, several cases with co-occurring
BCR-ABL1 and JAK2 V617F or CALR have been identified with a frequency
of 0.2-2.5% in the European population. The tyrosine kinase
abnormalities appeared to affect independent subclones because imatinib
mesylate (IM) treatment induced Ph+-CML remission, whereas the
JAK2V617F clone either persisted or clinically expanded after a major
response of Ph+-clone.
Patients and Methods